SYMPOSIUM OVERVIEW

OVERVIEW

Since the inaugural SIF 2004, there has been a spectacular technology evolution in the management of cardiovascular disease including coronary and valvular heart disease, cardiac rhythm management, congenital heart disease, peripheral vascular disorders as well as the diagnosis and treatment of heart failure patients.

It is with this in mind that SIF 2025 is designed to meet the ever-increasing needs of cardiovascular specialists in the diagnosis and management of complex cardiovascular disease. This live, comprehensive, state-of-the-art four-day symposium will provide an in-depth review of the most relevant advances in the treatment of heart and vascular disease. The SIF 2025 organizing committee is committed to creating a thorough, all-encompassing scientific curriculum.

As in the past, SIF 2025 will include a variety of specialty symposia along with Industry-sponsored workshops. Given the rapid evolution in diagnostic and therapeutic options for the treatment of coronary artery disease, the SIF Faculty will review the most pertinent diagnostic studies and management issues pertaining to complex coronary intervention. Advances in invasive coronary imaging and physiologic assessment will be highlighted with emphasis on FFR, IVUS and OCT guided coronary intervention.

SIF 2025 has been designed to provide physicians, nurses, and allied health participants the most comprehensive, state-of-the-art review of pathophysiologic disease mechanism, diagnostic imaging and expert management strategies for the treatment of those afflicted with advanced cardiovascular disorders. To that end, each day will begin and end with a series of complex case vignettes in which faculty and attendees “co-participate” in problem solving in an open-mic format. The goal of this four-day CME Symposium is simple: Provide attendees the requisite skills to advance bedside patient management, apply innovative therapies in the most practical manner, thus quantifiably improving the outcomes of patients suffering from cardiovascular disease.

Target Audience

The 2025 Scottsdale Interventional Forum has been designed to meet the educational needs of interventional and general cardiologists, cardiology fellows, cardiovascular surgeons and other vascular specialists, interventional radiologists, cath lab nurses and technicians as well as other medical professionals who have an interest in heart and vascular medicine.

Symposium Educational Objectives

At the conclusion of this CME Symposium, attendees should be able to:

  • Explain the role of mechanical circulatory support in patients undergoing complex coronary intervention.
  • Discuss novel stent platforms and the regulatory pathway to FDA approval.
  • Formulate a practical understanding of newer methodologies for plaque and calcium modification in coronary disease management.
  • Comprehend the emerging role of catheter-based revascularization in complex lesion subsets including unprotected left main coronary disease and multi vessel coronary artery disease.
  • Explain the relative merits of surgical vs. percutaneous revascularization in diabetic patients with complex coronary anatomy.
  • Discuss the role for advanced imaging in cardiovascular disease management including noninvasive imaging and high resolution invasive coronary imaging (OCT and IVUS).
  • Describe the emerging role of mechanical left atrial appendage therapy, novel Cerebral Embolic Protection devices and adjunctive devices in the management of structural heart disease.
  • Advance the knowledge of radial-based and other alternative access approaches to cardiovascular disease therapy.
  • Define the role of transcatheter and surgical therapies for patients with advanced aortic stenosis and aortic insufficiency.
  • Define the role of transcatheter aortic valve replacement (TAVR) in symptomatic, moderate severity aortic stenosis patients.
  • Describe the catheter-based therapies for those with degenerative and functional mitral valve disorders.
  • Define emerging therapies for patients with tricuspid and pulmonic valve disease.
  • Review the most relevant trials in coronary and structural heart disease which will shape the immediate future of patient management.
  • Review the most relevant recent trials in antiplatelet and antithrombotic management.